—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Johnson & Johnson (JNJ) — chart, structure and Closelooknet read

The Closelooknet read

Johnson & Johnson develops, makes and sells healthcare products worldwide through two arms: Innovative Medicine, covering prescription treatments for cancer, immune disease, infection and heart and metabolic conditions, and MedTech, covering surgical, orthopaedic, cardiovascular and vision products, including contact lenses and lenses used in cataract surgery. It sells through wholesalers, distributors, hospitals and clinicians rather than direct to patients in most cases.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Research diary readings, not advice.

Pick a ticker to load its detail page.

The desk on JNJ

What this diary said about Johnson & Johnson, what it holds and what would change its view — in its own words, dated. Investment diary, not advice.

What we said

Our record on JNJ

Every scored call, pick and trade this diary has made on Johnson & Johnson, with the outcome where it is known.

Signals for this name

Every Closelooknet reading that exists for JNJ, from the same nightly bakes the boards use. Research diary readings, not advice.

Mentioned on Closelooknet 11 pieces · newest: Morning 10, “AI Trade — Asia bounces, Kospi +3.3%; Nasdaq-100 holds its support line, Jakarta −10.8% on MSCI” (2026-10-16)

Mentioned on Closelooknet

Where JNJ appears in the diary — 11 pieces, newest first. Every link is our own writing.

Long reads

Dailies

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 47/100 · S&P 500 fund at 48, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-06
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 60th percentile of the window, -22.8% over 20 sessions. Factor regime → 2026-11-06
  • Sovereign pressure Index -2.05 · down 2.95 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-05
How it trades on rate days beta 0.44 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How JNJ has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.44 — tends to move with bonds for every 1% move in TLT (20+ year Treasuries), Johnson & Johnson moved 0.44% on average · correlation 0.20 · higher than 38% of US names
  • Beta, last 3 months 0.67 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.59% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.56% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - General · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against JNJ on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Johnson & Johnson

JNJ in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Johnson & Johnson develops, makes and sells healthcare products worldwide through two arms: Innovative Medicine, covering prescription treatments for cancer, immune disease, infection and heart and metabolic conditions, and MedTech, covering surgical, orthopaedic, cardiovascular and vision products, including contact lenses and lenses used in cataract surgery. It sells through wholesalers, distributors, hospitals and clinicians rather than direct to patients in most cases. It is based in New Brunswick, New Jersey.
Where it sits in the stack
The company carries no seat in our Rubin index, the diary's AI build-out gauge, so it sits outside that stack entirely. Within our wider universe it falls into the healthcare sector, drug manufacturers group, and the diary has grouped it among the slow-compounder names alongside consumer-staples and industrials peers in a covered-call income piece.
Who it is priced against
The diary has clustered it with other slow-moving dividend payers such as Coca-Cola, Procter & Gamble, Kimberly-Clark, 3M, Consolidated Edison, Abbott, Marsh McLennan, Emerson and Illinois Tool Works; the market's usual comparison beyond that list is Pfizer.
Why Closelooknet tracks it
It sits in the Dow Jones Industrial Average and turns up repeatedly in the diary's Daily Pulse notes, most often flagged by the Pattern Scanner as a support-confluence setup in a yellow regime. It carries no Closelooknet score, so that read is still being built. Analysts covering it have raised their price target, per the diary's most recent reading.
What the diary watches
Whether it keeps appearing among the Pattern Scanner's support-confluence names alongside cyclical stocks like Northrop Grumman and McDonald's, which the diary reads as a signal that defensive positioning is broadening.

Johnson & Johnson (JNJ) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: JNJ news on the tape · index compare · sector dispersion · scanner.

The Street on this name 5 analyst actions on the wire · latest: downgrade by Johnson Rice, 2026-10-21

The Street on this name

Analyst actions and the latest print for JNJ from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Downgrade Johnson Rice — Buy → Hold Downgraded to Hold from Buy 2026-10-21
  • Price target Wells Fargo — target 287 from 275 Target raised to $287 from $275 (+13.3% to spot) 2026-10-16
  • Price target Bernstein SocGen Group — target 270 Target set to $270 (+3.9% to spot) 2026-10-15

5 actions on the analyst wire since 2026-08-13: 1 downgrade, 4 target changes. Analyst wire → · Earnings wire →

Dividends and capital return trailing yield 1.95%, quarterly · last 1.34 USD on 2026-08-25

Dividends and capital return

What JNJ pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 5.30 USD per share · a 1.95% yield on the 2026-11-05 close 4 distributions, paid quarterly 2026-11-05
  • Change on the year +4.5% against the prior twelve months prior twelve months 5.08 USD per share
  • Last distribution 1.34 USD per share as the price series records it, within days of the ex-date 2026-08-25
  • By calendar year 2023: 1.19 USD (partial) · 2024: 4.91 USD · 2025: 5.14 USD · 2026: 4.00 USD to date first distribution recorded in the three-year window: 2023-11-20

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-06

Quick answers

What is Johnson & Johnson (JNJ)?

Johnson & Johnson trades as JNJ on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-11-06.

Is JNJ in a Closelooknet index?

Not currently — Johnson & Johnson is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-06.

What is Johnson & Johnson's earnings print record?

Across the 11 prints Closelooknet covers, Johnson & Johnson beat EPS estimates 10 times and revenue estimates 10 times; the three-day reactions split 1 up, 10 flat and 0 down (moves beyond ±3%), as of the 2026-10-13 card. The full print-record card carries the per-print history.

Where does JNJ trade against its moving averages?

Johnson & Johnson trades 2.5% above its 50-day and 9.9% above its 200-day moving average (3.2% above its 20-day). As of 2026-11-05 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Johnson & Johnson compare with its peers?

Against its peer group (Drug Manufacturers - General · US), Johnson & Johnson (JNJ) sits 3.4% below its 52-week high, 2.5% above its 50-day average; Amgen Inc (AMGN) is 0.8% below, GSK plc (GSK) is 16.1% below, Sanofi ADR (SNY) is 6.0% below, as of 2026-11-05. Put any of them next to JNJ in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Johnson & Johnson trade when bond yields rise?

Over the past year Johnson & Johnson had a beta of 0.44 to TLT, the long-dated Treasury fund — it tends to move with bonds, higher than 38% of US names. On the 10 sessions in which long bonds fell most it moved −0.59% on average, against −0.74% for the S&P 500. As of 2026-11-05; The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Johnson & Johnson?

Johnson & Johnson appears in 11 Closelooknet pieces as of 2026-11-06, most recently Morning 10: AI Trade — Asia bounces, Kospi +3.3%; Nasdaq-100 holds its support line, Jakarta −10.8% on MSCI (2026-10-16); Morning 10: ASML — record €11.7 billion quarter and sold out into 2028; inflation at 12:30 UTC (2026-10-14); Midday 10: Earnings — J&J −6.2% and Citi −3.8% after beats; Micron −5.1%, chip fund back under its 50-day line (2026-10-13). What Closelooknet said most recently: Going into the last day: UnitedHealth 406.89 (+7.7% vs entry, above its paid line of 389.09); Wells Fargo 82.82 (+2.6%, paid line 83.17); Johnson & Johnson 253.66 (+2.0%); JPMorgan 336.18 (+1.4%); Goldman Sachs 892.61 (+0.1%); Citi 123.39… (Morning 10, 2026-10-16). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does Johnson & Johnson do?

Johnson & Johnson develops, makes and sells healthcare products worldwide through two arms: Innovative Medicine, covering prescription treatments for cancer, immune disease, infection and heart and metabolic conditions, and MedTech, covering surgical, orthopaedic, cardiovascular and vision products, including contact lenses and lenses used in cataract surgery. It sells through wholesalers, distributors, hospitals and clinicians rather than direct to patients in most cases. It is based in New Brunswick, New Jersey. The diary has clustered it with other slow-moving dividend payers such as Coca-Cola, Procter & Gamble, Kimberly-Clark, 3M, Consolidated Edison, Abbott, Marsh McLennan, Emerson and Illinois Tool Works; the market's usual comparison beyond that list is Pfizer. (Company snapshot of 2026-09-17.)

Where does Johnson & Johnson sit in the AI build-out?

The company carries no seat in our Rubin index, the diary's AI build-out gauge, so it sits outside that stack entirely. Within our wider universe it falls into the healthcare sector, drug manufacturers group, and the diary has grouped it among the slow-compounder names alongside consumer-staples and industrials peers in a covered-call income piece. It sits in the Dow Jones Industrial Average and turns up repeatedly in the diary's Daily Pulse notes, most often flagged by the Pattern Scanner as a support-confluence setup in a yellow regime. It carries no Closelooknet score, so that read is still being built. Analysts covering it have raised their price target, per the diary's most recent reading. (Company snapshot of 2026-09-17.)

Does Johnson & Johnson pay a dividend?

Johnson & Johnson has paid 5.30 USD per share over the last twelve months, paid quarterly, a trailing yield of 1.95% on the 2026-11-05 close; the last distribution recorded in the price series was 1.34 USD on 2026-08-25. As of 2026-11-05; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Johnson & Johnson recently?

The most recent analyst action on Johnson & Johnson on the Closelooknet wire is a downgrade by Johnson Rice on 2026-10-21 (Buy → Hold). 5 actions on the analyst wire since 2026-08-13: 1 downgrade, 4 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for JNJ, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.